Tiara Rose Moore, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 103 Shenandoah Junction Rd, Shenandoah Junction, WV 25442 Phone: 304-728-7250 |
News Archive
Many cancers only become a mortal danger if they form metastases elsewhere in the body. Such secondary tumours are formed when individual cells break away from the main tumour and travel through the bloodstream to distant areas of the body.
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2011. The Company reported a loss from operations of $(4.8) million compared to a loss from operations of $(15.0) million in the 2010 first quarter.
Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.
Columbia Laboratories, Inc. announced that in a special meeting of stockholders held this morning, stockholders approved the sale of substantially all of Columbia's progesterone related assets to Watson Pharmaceuticals, Inc.. Stockholders also voted to increase the number of authorized shares of Columbia's common stock, $0.01 par value per share, from 100,000,000 to 150,000,000.
Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.
› Verified 7 days ago